Patients with hepatitis-associated aplastic anemia (HAA) who undergo living-donor liver transplantation (LDLT) have a poor prognosis with infectious and bleeding complications. Immunosuppressive therapy (IST) combined with thrombopoietin (TPO) receptor agonists is considered effective for aplastic anemia. There are no data on the benefits of adding TPO receptor agonists to IST for HAA. We present the case of a child with severe HAA who underwent LDLT, and who achieved rapid blood cell recovery with IST combined with romiplostim, a TPO receptor agonist. This case suggests that IST combined with TPO receptor agonists may be beneficial for HAA patients undergoing LDLT.